OliX Pharmaceuticals (226950) Financial Statements

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025-30.0 billion KRW-15.7 billion KRW[source]
2024-30.9 billion KRW-40.7 billion KRW[source]
2023-18.2 billion KRW-19.1 billion KRW[source]
2022-22.4 billion KRW-21.9 billion KRW[source]
2021-25.4 billion KRW-30.3 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025195.7 billion KRW47.1 billion KRW148.7 billion KRW[source]
202473.9 billion KRW56.5 billion KRW17.4 billion KRW[source]
2023100.9 billion KRW50.3 billion KRW50.6 billion KRW[source]
2022130.7 billion KRW63.2 billion KRW67.5 billion KRW[source]
202185.0 billion KRW64.2 billion KRW20.8 billion KRW[source]

This company has no revenue account in the DART financial statements. Industry-specific accounts such as insurance or interest income are not converted to revenue.